ARK Invest

xAI is charting a course for alternative compute sources what will unlock unique scaling vectors relative to the competition. An effort that's success will hinge on the team's ability to build a capable agent that can run on your Tesla's hardware. Will you lend you car to the Digital Optimus army if available in 6 months?

Another round trip! Vinay Prasad is leaving the FDA for the second time in roughly a year. His tenure brought high-profile rejections that surprised rare disease developers, raising questions about whether the FDA's messaging on flexibility matched its actions. My take: the reforms that started taking shape over the last year aren't leaving with him. One pivotal trial as the new default. A "plausible mechanism" pathway to streamline approvals for therapies targeting diseases with known biological causes. A national priority review program. These address real structural bottlenecks in drug development, but they're not enough. Case in point: Makary said today that China initiates four times the Phase 1 trials as the US and China is looking to speed that up even further. To keep competitive the FDA is pushing IRB reforms to close that gap. So will this year bring continuous trials, faster Phase 1 entry, more agile oversight? The reform direction is set. The question is the pace now.